Gene Therapy

anc80 in cochlea

Gene therapy restores hearing in deaf mice… down to a whisper

February 8, 2017

Improved delivery vector better penetrates the inner ear, also restores balance in a mouse model of Usher syndrome 

Boston, Mass. — In the summer of 2015, a team at Boston Children’s Hospital and Harvard Medical School reported restoring rudimentary hearing in genetically deaf mice using gene therapy. Now the Boston Children’s research team reports restoring a much… Read more about Gene therapy restores hearing in deaf mice… down to a whisper

Luk Vandenberghe

Selecta Biosciences obtains exclusive license to proprietary gene therapy vector from Massachusetts Eye and Ear

May 19, 2016

Selecta is licensing Anc80 from Massachusetts Eye and Ear for a rare genetic disease with options on additional pre-specified indications. By combining Anc80 with Selecta’s investigational drug candidate, SVP-Rapamycin (SEL-110), Selecta is seeking to advance a new gene therapy platform designed to avoid several immunogenicity challenges that limit the development of gene therapies today 

Watertown, Mass. — Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, announced… Read more about Selecta Biosciences obtains exclusive license to proprietary gene therapy vector from Massachusetts Eye and Ear